ATR

Serine/threonine-protein kinase ATR

91,200 patent compounds predicted against ATR, 43,674 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL318797	0.68	19/20
Benzoic Acid (SCHEMBL412075)	0.58	14/20
SCHEMBL336653	0.53	14/20
SCHEMBL441294	0.51	14/20
SCHEMBL411951	0.75	12/20
SCHEMBL439516	0.53	12/20
SCHEMBL373050	0.56	11/20
SCHEMBL373051	0.56	11/20
SCHEMBL373052	0.56	11/20
SCHEMBL373155	0.44	11/20
SCHEMBL373156	0.44	11/20
SCHEMBL373157	0.44	11/20
SCHEMBL411424	0.56	10/20
SCHEMBL319167	0.56	10/20
SCHEMBL247192	0.47	10/20
SCHEMBL411857	0.67	9/20
SCHEMBL413176	0.64	9/20
SCHEMBL407802	0.57	9/20
SCHEMBL410132	0.56	9/20
Hydrochloric Acid (SCHEMBL411390)	0.56	9/20

Germline variants in ATR on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full ATR gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to ATR by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers	PHASE1/PHASE2	NOT_YET_RECRUITING
Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers	PHASE1/PHASE2	COMPLETED
Study Of ATRN-119 In Patients With Advanced Solid Tumors	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors	PHASE1/PHASE2	RECRUITING
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors	PHASE1/PHASE2	RECRUITING
Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Combining Neo-adjuvant ATR-inhibition With Nodal SBRT for Early-stage Resectable HPV+ OPSCCs	PHASE1/PHASE2	NOT_YET_RECRUITING
M6620 (VX-970) in Selected Solid Tumors	PHASE2	COMPLETED
A Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia	PHASE2	COMPLETED
A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Effects of Vitamin B3 in Patients With Ataxia Telangiectasia	PHASE2	COMPLETED
Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer	PHASE2	ACTIVE_NOT_RECRUITING
Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer	PHASE2	COMPLETED
ATr Inhibitor in Combination With Olaparib/Durvalumab (MEDI4736) in Gynaecological Cancers With ARId1A Loss or no Loss	PHASE2	ACTIVE_NOT_RECRUITING
A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency	PHASE2	COMPLETED
Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation	PHASE2	UNKNOWN
Phase 1 Study of ATR-002	PHASE1	COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
Study of AZD6738, DNA Damage Repair/Novel Anti-cancer Agent, in Combination With Paclitaxel, in Refractory Cancer	PHASE1	COMPLETED
Phase I Study of FXS887 in the Treatment of Solid Tumors	PHASE1	NOT_YET_RECRUITING
First-in-human Single and Multiple Dose Trial of ATR-258	PHASE1	COMPLETED
Phase I Study to Assess Safety of AZD6738 Alone and in Combination With Radiotherapy in Patients With Solid Tumours	PHASE1	UNKNOWN
M6620 Plus Standard Treatment in Oesophageal and Other Cancer	PHASE1	COMPLETED
AZD6738 for Patients With Progressive MDS or CMML	PHASE1	ACTIVE_NOT_RECRUITING
Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	PHASE1	ACTIVE_NOT_RECRUITING
First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas	PHASE1	COMPLETED
AZD6738 & Gemcitabine as Combination Therapy	PHASE1	UNKNOWN
A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors	PHASE1	COMPLETED
Prospective Validation of a DNA Damage Repair-Hippo Pathway Signature in Patients With Advanced Gastric Cancer	nan	UNKNOWN
Tissue Collection for Correlation Between ATM Alterations by Next-Generation Sequencing and ATM Loss-of-Protein	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a ATR binder may also engage these)

Protein	Name	Similarity
Q9JKK8	—	1.000	Q9JKK8 →
Q9DE14	—	1.000	Q9DE14 →
Q6CAD2	—	1.000	Q6CAD2 →
A1Z8X3	—	1.000	A1Z8X3 →
Q8BKX6	—	0.999	Q8BKX6 →
Q9FKS4	—	0.998	Q9FKS4 →
E1C231	—	0.998	E1C231 →
P97313	—	0.997	P97313 →
O14715	—	0.997	O14715 →
PI4KA	Phosphatidylinositol 4-kinase alpha	0.997	landscape →
Q5MNV8	—	0.997	Q5MNV8 →
Q9DEI1	—	0.997	Q9DEI1 →
Q9VXG8	—	0.997	Q9VXG8 →
O08662	—	0.997	O08662 →
F4I893	—	0.997	F4I893 →
P32333	—	0.997	P32333 →
Q99666	—	0.997	Q99666 →
P42173	—	0.997	P42173 →
SMG1	Serine/threonine-protein kinase SMG1	0.997	landscape →
GEMIN4	Gem-associated protein 4	0.997	landscape →
Q9SXA1	—	0.997	Q9SXA1 →
C5J7W8	—	0.996	C5J7W8 →
Q70PP2	—	0.996	Q70PP2 →
Q18892	—	0.996	Q18892 →
O02811	—	0.996	O02811 →
Q751Y8	—	0.996	Q751Y8 →
Q9C8Z4	—	0.996	Q9C8Z4 →
Q7Z3J3	—	0.996	Q7Z3J3 →
P0DJD0	—	0.996	P0DJD0 →
Q80UK8	—	0.996	Q80UK8 →